Company intelligence / Profile preview

Shanghai Argo Biopharmaceutical Co., Ltd.

Shanghai, Shanghai, Chinaargobiopharma.com ↗
Ownership
Private
Development stage
Phase 2
01

Overview

The company has demonstrated well-tolerated safety profiles across its leading clinical programs. It has completed phase I trials for several siRNA candidates targeting cardiovascular conditions and initiated phase II studies. Its pipeline shows best-in-class potential leveraging the RADS platform to develop next-generation siRNA drugs aiming to reduce dosing frequency significantly.

Therapeutic areas
Metabolic DisordersRare DiseasesImmunologyCardiovascularNeurologyInfectious Diseases
Modalities
Small interfering RNA (siRNA)RNA interference (RNAi) therapeuticsChemical drugs (limited presence)
Industry
Biotech
02

Drug pipeline

26 assets

BW-20805

2

25 more assets in the full pipeline.

03

Partnerships

Novartis PHARMA AG – multi-program exclusive license and collaboration agreements signed January 2024 involving cardiovascular disease assets with upfront payments of $185 million plus milestones and royalties. Novartis holds ex-Greater China rights on one program plus worldwide rights on another[7][8].

Beyond the preview

Go deeper on Shanghai Argo Biopharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Argo Biopharmaceutical Co., Ltd..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call